Marvel Biosciences Announces Letter Agreement For Market Stabilization and Liquidity Services
Marvel Biosciences Inc. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the “Consulting Agreement”) with Mr. Adam Smith of Red Cloud Securities Inc. (“Red Cloud”) to support Marvel’s market stabilization and...
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
Calgary, Alberta – (December 12, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204. To date, the Company’s MB-204 has shown positive and promising data addressing depression,...
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer’s and Depression
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials. “We have significantly de-risked the...
Marvel Biosciences Announces Director Appointment and Resignation
CALGARY, Alberta – (November 24, 2022) – Marvel Biosciences Inc. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors. Babak Pedram, Director Mr. Pedram brings a vast degree of business, capital markets and scientific...
Marvel Biosciences’ Lead Drug Candidate MB-204 Demonstrated a 400% Survival Rate Increase in Animals Treated with the Cancer Treatment Cisplatin
Calgary, Alberta–(November 22, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment,...
Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity Over FDA-Approved Istradefylline in Head-to-Head Pre-clinical Studies
Calgary, Alberta–(November 14, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre-clinical and in depressive...
Marvel Biosciences’ Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer’s Disease and Depression
Marvel Biosciences’ Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer’s Disease and Depression Calgary, Alberta–(November 7, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announced today that in a pre-clinical mouse study conducted by the Company, its lead...
Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer’s Further Advancing Towards FDA Phase I Human Trials
Calgary, Alberta–(November 1, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”). The engineering run material...
Marvel Biosciences Advances Closer to Human Trials after the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
CALGARY, Alberta – (October 25, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company’s lead drug candidate low toxicity characteristic. "We have now completed and further validated MB-204’s safety profile through this...
Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
CALGARY, Alberta – (October 17, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity. MB-204 is the Company’s lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson’s disease drug) and is a blood...